The membranes were then incubated overnight at 4 C with the following 14 primary antibodies diluted to 1:2000 in 1% TBST: mouse anti-CYP1A2 (sc-53614), mouse anti-PFK-1 (sc-166722), mouse anti-fatty acid synthase (A-5) (sc-55580), mouse anti-PKLR (sc-133222), mouse anti-GSTM1 (sc-517262), mouse anti-CROT (H-1)(sc-365976), mouse anti-PROHIBITIN 2 (A-2) (sc-133094), mouse anti-ATP5F1 (C-12) (sc-514419), mouse anti-CYP4A1(clo1) (sc-53248), mouse anti-PKM (C-11) (sc-365684), mouse anti-GSTT2 (D-1) (sc-514667), mouse anti-FAAH (27-) (sc-100739), mouse anti-17-HSD2 (E-7) (sc-374150), mouse anti-GSTA1/2/5 (E-6) (sc-398714), mouse anti-ETFDH (D-2) (sc-515202), mouse anti-LFABP (C-4) (sc-374537), mouse anti-LMP2,1i (A-1) (sc-271354, LOT#B1611), mouse anti-MECL-1(71P6) 2i (sc-130295) (all from Santa Cruz), mouse anti-5i (1:2000, custom made by Abgent), and rabbit anti-PSMA6 (1:20,000
More human research is needed
Survival and development assays in C
three amino acids molecules in the three-dimensional structure
These differences highlight the need for tailored therapeutic strategies, EHS may benefit from early anti-pyroptotic/anti-necroptotic agents, while CHS requires prioritized gut barrier protection and anti-apoptotic interventions
